A phase II trial of TPIV-200 in patients with triple negative breast cancer
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2017
At a glance
- Drugs TPIV 200 (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Advanced breast cancer
- Focus Proof of concept; Therapeutic Use
- 12 Dec 2017 According to a TapImmune media release, first patient has been enrolled in this study.
- 12 Dec 2017 Status changed from planning to recruiting, according to a TapImmune media release.
- 14 Nov 2017 According to a TapImmune media release, patient dosing is expected to begin by year end 2017.